Since Biden took over, Big Pharma has spent $205 million to protect drug price status quo, analysis finds

The election of President Joe Biden—and his campaign promise to reduce drug prices—was a call to arms for the pharmaceutical industry.

How invested is Big Pharma in protecting its ability to charge enormous prices for its products?

Since 2020, the year Biden moved into the White House, the industry has spent more than $205 million battling to preserve the status quo, an analysis from Accountable.US finds. The figure includes $149 million in lobbying efforts aimed specifically at drug pricing and more than $57 million in television, cable, radio and social media ads opposing Medicare price negotiations.